How to buy fotantinib/fotantinib at a more cost-effective price

Fostamatinib is an oral spleen tyrosine kinase inhibitor (SYK inhibitor), mainly used to treat refractory blood diseases such as chronic immune thrombocytopenia (ITP). Since this drug is an imported original prescription drug and has not yet been officially launched in mainland China, it cannot be purchased directly in domestic pharmacies or hospitals. Patients who want to obtain medicines mostly obtain genuine medicines through overseas drug purchase or cross-border medical platforms. According to the quotation information of the international pharmaceutical market, fostatinib is available as an original drug in the United States and Germany. Its specifications are 100 mg 60 tablets and 150 mg 60 tablets. The most common specifications are 60 mg tablets and 150 mg 60 tablets. The price of each box ranges from approximately RMB 20,000 to RMB 40,000. Due to differences in exchange rates, channels and taxes, the actual purchase cost will vary.

In order to purchase fostatinib at a more cost-effective price, patients usually choose to cooperate with regular overseas pharmacies or pharmaceutical company agents certified byFDA and EMA, and ship directly from official channels to avoid high premiums caused by intermediate links. Some international Patient Assistance Programs (PAPs) may also provide drug subsidies or discounted drug purchase channels, especially for long-term drug users.

From the perspective of long-term treatment, patients can obtain more favorable wholesale prices by evaluating the medication cycle, dosage and course of treatment, and negotiating with overseas pharmacies to purchase multiple boxes together. It is worth noting that fostatinib has high requirements for storage temperature and transportation conditions. Choose a platform with cold chain transportation qualifications to purchase it to ensure stable drug quality.

At present, there are no generic fostatinib drugs on the market in China, so in the foreseeable future, imported original drugs will still be the main source. If this drug is approved for marketing or included in medical insurance in China in the future, the threshold for its clinical use will be significantly lowered.

Reference materials:https://go.drugbank.com/drugs/DB12010